Date: 2011-01-12
Type of information: Grant
Company: Celyad previously known as Cardio3 Biosciences (Belgium)
Investors: Walloon Region (Belgium) - European Commission’s Seventh Framework Program (FP7)
Amount: €3.1 million
Funding type: cash advance, grant
Planned used: The Walloon Region funding takes the form of recoverable cash advances and will be used to industrialise a number of Cardio3 BioSciences projects including establishing a new bioreactor for the production of the Company’s lead product, C3BS-CQR-1 (C-Cure®), a highly innovative stem cell approach for the treatment of heart failure.
Others: Cardio3 BioSciences has secured a total of €3.1 million in non-dilutive funding from the Walloon Region and the European Commission’s Seventh Framework Programme (FP7).
Therapeutic area: Cardiovascular diseases
